AR105483A1 - Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona - Google Patents
Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanonaInfo
- Publication number
- AR105483A1 AR105483A1 ARP160101900A ARP160101900A AR105483A1 AR 105483 A1 AR105483 A1 AR 105483A1 AR P160101900 A ARP160101900 A AR P160101900A AR P160101900 A ARP160101900 A AR P160101900A AR 105483 A1 AR105483 A1 AR 105483A1
- Authority
- AR
- Argentina
- Prior art keywords
- fumarate salt
- nmr spectrum
- azetidin
- piperidin
- difluoro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Reivindicación 1: Una sal de fumarato cristalina de (S)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona. Reivindicación 2: La sal de fumarato cristalina de la reivindicación 1, designada como forma A, en donde la sal de fumarato cristalina se caracteriza por al menos uno de lo siguiente: (i) un espectro ¹H NMR en d₆ DMSO sustancialmente como se describe en la figura 2; (ii) un espectro ¹³C NMR en d₆ DMSO sustancialmente como se describe en la figura 3; (iii) un espectro ¹³C NMR en estado sólido con tres o más picos seleccionados de 175,3, 173,6, 117,5, 155,5 y 153,5 ± 0,2 ppm; (iv) un espectro ¹³C NMR en estado sólido sustancialmente como se describe en la figura 4; (v) un patrón de difracción de rayos X en polvo (CuKa l = 1,5418 Å) que comprende tres o más valores de 2q seleccionados de 4,6, 12,1, 13,2, 13,6 y 14,5 ± 0,2 º2q, en donde la medición de la forma cristalina es a temperatura ambiente; (vi) un patrón de difracción de rayos X en polvo (XRPD) sustancialmente de acuerdo con el patrón que se muestra en la figura 10; y (vii) un termograma de calorimetría diferencial de barrido sustancialmente de acuerdo con la figura 8.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187009P | 2015-06-30 | 2015-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105483A1 true AR105483A1 (es) | 2017-10-11 |
Family
ID=56411938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101900A AR105483A1 (es) | 2015-06-30 | 2016-06-24 | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10590102B2 (es) |
| EP (1) | EP3317264A1 (es) |
| JP (3) | JP7338950B2 (es) |
| KR (1) | KR20180021775A (es) |
| CN (1) | CN107810183A (es) |
| AR (1) | AR105483A1 (es) |
| AU (2) | AU2016288209B2 (es) |
| CA (1) | CA2990222C (es) |
| CL (1) | CL2017003475A1 (es) |
| CO (1) | CO2018000086A2 (es) |
| CR (1) | CR20180056A (es) |
| HK (1) | HK1252433A1 (es) |
| IL (2) | IL256423B (es) |
| MA (1) | MA42301A (es) |
| MX (1) | MX2017017037A (es) |
| MY (1) | MY192545A (es) |
| PE (1) | PE20180692A1 (es) |
| PH (1) | PH12017502414A1 (es) |
| RU (2) | RU2762181C2 (es) |
| SG (1) | SG10202105196YA (es) |
| TW (2) | TWI710556B (es) |
| UA (1) | UA124728C2 (es) |
| WO (1) | WO2017004393A1 (es) |
| ZA (1) | ZA201708760B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2909188T1 (en) | 2012-10-12 | 2018-07-31 | Exelixis, Inc. | A novel process for the manufacture of compounds for use in the treatment of cancer |
| TWI804919B (zh) * | 2015-06-30 | 2023-06-11 | 美商建南德克公司 | 含藥物之立即釋放錠劑及形成該錠劑的方法 |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
| MX2019008458A (es) | 2017-01-17 | 2019-12-02 | Heparegenix Gmbh | Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos. |
| GB201717809D0 (en) * | 2017-10-30 | 2017-12-13 | Azad Pharmaceutical Ingredients Ag | Process for the production of cobimetinib |
| WO2020187674A1 (en) | 2019-03-15 | 2020-09-24 | Sandoz Ag | Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7956191B2 (en) | 2004-10-20 | 2011-06-07 | Merck Serono Sa | 3-arylamino pyridine derivatives |
| EP2266974A1 (en) | 2005-05-23 | 2010-12-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-Quinolin-2-one lactic acid salts |
| EA019983B1 (ru) | 2005-10-07 | 2014-07-30 | Экселиксис, Инк. | Ингибиторы mek и способы их применения |
| WO2008021389A2 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| CA2671982C (en) | 2006-12-14 | 2016-01-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| SI2909188T1 (en) | 2012-10-12 | 2018-07-31 | Exelixis, Inc. | A novel process for the manufacture of compounds for use in the treatment of cancer |
| CN109568312A (zh) | 2013-03-05 | 2019-04-05 | 田纳西大学研究基金会 | 用于治疗癌症的化合物 |
| EP2968540A2 (en) | 2013-03-14 | 2016-01-20 | Genentech, Inc. | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
-
2016
- 2016-06-24 AR ARP160101900A patent/AR105483A1/es unknown
- 2016-06-30 CN CN201680039354.4A patent/CN107810183A/zh active Pending
- 2016-06-30 MY MYPI2017001962A patent/MY192545A/en unknown
- 2016-06-30 CA CA2990222A patent/CA2990222C/en active Active
- 2016-06-30 TW TW105120825A patent/TWI710556B/zh active
- 2016-06-30 KR KR1020187000067A patent/KR20180021775A/ko not_active Application Discontinuation
- 2016-06-30 IL IL256423A patent/IL256423B/en unknown
- 2016-06-30 WO PCT/US2016/040444 patent/WO2017004393A1/en active Application Filing
- 2016-06-30 MX MX2017017037A patent/MX2017017037A/es unknown
- 2016-06-30 UA UAA201800769A patent/UA124728C2/uk unknown
- 2016-06-30 JP JP2017568050A patent/JP7338950B2/ja active Active
- 2016-06-30 PE PE2017002869A patent/PE20180692A1/es unknown
- 2016-06-30 RU RU2018103172A patent/RU2762181C2/ru active
- 2016-06-30 IL IL295052A patent/IL295052A/en unknown
- 2016-06-30 RU RU2021132394A patent/RU2021132394A/ru unknown
- 2016-06-30 EP EP16738971.7A patent/EP3317264A1/en active Pending
- 2016-06-30 CR CR20180056A patent/CR20180056A/es unknown
- 2016-06-30 SG SG10202105196YA patent/SG10202105196YA/en unknown
- 2016-06-30 AU AU2016288209A patent/AU2016288209B2/en active Active
- 2016-06-30 MA MA042301A patent/MA42301A/fr unknown
- 2016-06-30 TW TW109136325A patent/TWI775187B/zh active
-
2017
- 2017-12-21 ZA ZA2017/08760A patent/ZA201708760B/en unknown
- 2017-12-22 US US15/852,280 patent/US10590102B2/en active Active
- 2017-12-22 PH PH12017502414A patent/PH12017502414A1/en unknown
- 2017-12-29 CL CL2017003475A patent/CL2017003475A1/es unknown
-
2018
- 2018-01-05 CO CONC2018/0000086A patent/CO2018000086A2/es unknown
- 2018-09-12 HK HK18111734.8A patent/HK1252433A1/zh unknown
-
2020
- 2020-01-17 US US16/746,161 patent/US11254649B2/en active Active
- 2020-11-05 JP JP2020184868A patent/JP2021035967A/ja not_active Withdrawn
-
2021
- 2021-01-14 AU AU2021200202A patent/AU2021200202B2/en active Active
- 2021-11-08 US US17/521,396 patent/US20220056010A1/en not_active Abandoned
-
2022
- 2022-11-07 JP JP2022178184A patent/JP2023025000A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105483A1 (es) | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona | |
| TN2015000175A1 (en) | Heteroaryl substituted pyridyl compounds useful as kinase modulators | |
| FR2966474B1 (fr) | Procede de fabrication d'un materiau nanocristallin | |
| WO2014147525A3 (en) | Perylenemonoimide and naphthalenemonoimide derivatives and their use in dye-sensitized solar cells | |
| HRP20220622T1 (hr) | Kristalni oblik 1-(4-1-(2,6-difluorobenzil)-5-dimetilaminometil-3-(6-metoksipiridazin-3-il)-2,4-diokso-1,2,3,4-tetrahidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metoksiurea | |
| FR2918050B1 (fr) | Solide cristallise izm-2 et son procede de preparation | |
| MY150989A (en) | Benzothiazole compounds useful for raf inhibition | |
| PE20160523A1 (es) | Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis | |
| MY173946A (en) | (6s,9as)-n-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl) azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1h-pyrazino[2,1-c] [1,2,4]triazine-1-carboxamide compound | |
| MX2013000446A (es) | Formas solidas de romdepsina y sus usos. | |
| RS54730B1 (sr) | Inhibitori beta sekretaze | |
| MY176126A (en) | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | |
| AR082804A1 (es) | Formas cristalinas de un inhibidor del factor xa | |
| MY152972A (en) | Azabicyclo compound and salt thereof | |
| RU2016146119A (ru) | Новый кристалл тетрациклического соединения | |
| AR074507A1 (es) | Forma cristalina del clorhidrato de nalmefeno dihidratado, metodos para obtenerla, composiciones farmaceuticas que contienen dicha forma cristalina, uso de las mismas en el tratamiento del alcoholismo y un metodo de recuperacion de la forma cristalina anhidra. | |
| PH12015501807A1 (en) | Vortioxetine manufacturing process | |
| WO2016171465A3 (ko) | 헤테로환 화합물 및 이를 포함하는 유기 태양 전지 | |
| CR20140345A (es) | Nuevas formas y sales de un dihidropirrolo [1,2-c] imidazolilo, inhibidor de la aldosterona sintasa o aromatasa | |
| MX2016004963A (es) | Sal y formas cristalinas de inhibidores de quinasa tipo polo-4. | |
| MX2015015841A (es) | Compuestos de fenoxietil dihidro-1h-isoquinolina. | |
| EA201890476A1 (ru) | ЗАМЕЩЕННЫЕ 1,2-ДИГИДРО-3H-ПИРРОЛО[1,2-c]ИМИДАЗОЛ-3-ОНЫ В КАЧЕСТВЕ АНТИБАКТЕРИАЛЬНЫХ СРЕДСТВ | |
| FR2924110B1 (fr) | Solide cristallise izm-3 et son procede de preparation | |
| MX2015011857A (es) | Pigmento de pirocloro simultaneamente sustituido y estructuras relacionadas. | |
| ES2489467T3 (es) | Polimorfo novedoso del clorhidrato del éster (6-dimetilaminometil-2-naftalenílico) del ácido (4-hidroxicarbamoilfenil)-carbámico |